Logo image of CMAX

CAREMAX INC (CMAX) Stock Fundamental Analysis

NASDAQ:CMAX - Nasdaq - US14171W2026 - Common Stock - Currency: USD

0.4215  -0.15 (-26.22%)

After market: 0.3089 -0.11 (-26.71%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CMAX. CMAX was compared to 102 industry peers in the Health Care Providers & Services industry. CMAX has a bad profitability rating. Also its financial health evaluation is rather negative. CMAX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CMAX has reported negative net income.
In the past year CMAX has reported a negative cash flow from operations.
In the past 5 years CMAX always reported negative net income.
CMAX had a negative operating cash flow in each of the past 5 years.
CMAX Yearly Net Income VS EBIT VS OCF VS FCFCMAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -200M -400M -600M

1.2 Ratios

The Return On Assets of CMAX (-172.42%) is worse than 95.45% of its industry peers.
Industry RankSector Rank
ROA -172.42%
ROE N/A
ROIC N/A
ROA(3y)-37.96%
ROA(5y)N/A
ROE(3y)-373.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CMAX Yearly ROA, ROE, ROICCMAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

1.3 Margins

CMAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMAX Yearly Profit, Operating, Gross MarginsCMAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

More info and screens

0

2. Health

2.1 Basic Checks

CMAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CMAX has more shares outstanding
Compared to 1 year ago, CMAX has a worse debt to assets ratio.
CMAX Yearly Shares OutstandingCMAX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M
CMAX Yearly Total Debt VS Total AssetsCMAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

CMAX has an Altman-Z score of -3.22. This is a bad value and indicates that CMAX is not financially healthy and even has some risk of bankruptcy.
CMAX has a worse Altman-Z score (-3.22) than 87.27% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.22
ROIC/WACCN/A
WACC8.41%
CMAX Yearly LT Debt VS Equity VS FCFCMAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.23 indicates that CMAX may have some problems paying its short term obligations.
CMAX has a Current ratio of 0.23. This is amonst the worse of the industry: CMAX underperforms 93.64% of its industry peers.
CMAX has a Quick Ratio of 0.23. This is a bad value and indicates that CMAX is not financially healthy enough and could expect problems in meeting its short term obligations.
CMAX's Quick ratio of 0.23 is on the low side compared to the rest of the industry. CMAX is outperformed by 93.64% of its industry peers.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
CMAX Yearly Current Assets VS Current LiabilitesCMAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CMAX have decreased strongly by -1080.14% in the last year.
CMAX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.06%.
EPS 1Y (TTM)-1080.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)9.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.5%

3.2 Future

Based on estimates for the next years, CMAX will show a very strong growth in Earnings Per Share. The EPS will grow by 24.98% on average per year.
The Revenue is expected to grow by 16.33% on average over the next years. This is quite good.
EPS Next Y83.76%
EPS Next 2Y37.58%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next Year5.97%
Revenue Next 2Y18.46%
Revenue Next 3Y16.94%
Revenue Next 5Y16.33%

3.3 Evolution

CMAX Yearly Revenue VS EstimatesCMAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
CMAX Yearly EPS VS EstimatesCMAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CMAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CMAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMAX Price Earnings VS Forward Price EarningsCMAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMAX Per share dataCMAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 100 -100 200

4.3 Compensation for Growth

CMAX's earnings are expected to grow with 24.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.58%
EPS Next 3Y24.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMAX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAREMAX INC

NASDAQ:CMAX (11/27/2024, 9:32:53 PM)

After market: 0.3089 -0.11 (-26.71%)

0.4215

-0.15 (-26.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-22 2024-11-22/amc
Earnings (Next)N/A N/A
Inst Owners40.82%
Inst Owner Change-7.01%
Ins Owners22.94%
Ins Owner Change0%
Market Cap1.61M
Analysts45.71
Price Target43.25 (10160.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-28.17%
Min EPS beat(2)-29.48%
Max EPS beat(2)-26.86%
EPS beat(4)0
Avg EPS beat(4)-805.79%
Min EPS beat(4)-2482.51%
Max EPS beat(4)-26.86%
EPS beat(8)1
Avg EPS beat(8)-317.07%
EPS beat(12)3
Avg EPS beat(12)-265.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.7%
Min Revenue beat(2)-12.05%
Max Revenue beat(2)15.44%
Revenue beat(4)2
Avg Revenue beat(4)-4.22%
Min Revenue beat(4)-22%
Max Revenue beat(4)15.44%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)7
Avg Revenue beat(12)2.77%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)30.26%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-173.48
EYN/A
EPS(NY)-19.6
Fwd EYN/A
FCF(TTM)-16.26
FCFYN/A
OCF(TTM)-13.59
OCFYN/A
SpS205.92
BVpS-38.78
TBVpS-91.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -172.42%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.96%
ROA(5y)N/A
ROE(3y)-373.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.85%
Cap/Sales 1.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z -3.22
F-Score3
WACC8.41%
ROIC/WACCN/A
Cap/Depr(3y)46.3%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.82%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1080.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y83.76%
EPS Next 2Y37.58%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)9.06%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-11.5%
Revenue Next Year5.97%
Revenue Next 2Y18.46%
Revenue Next 3Y16.94%
Revenue Next 5Y16.33%
EBIT growth 1Y-369.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year79.29%
EBIT Next 3Y30.61%
EBIT Next 5Y17.36%
FCF growth 1Y-9.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.24%
OCF growth 3YN/A
OCF growth 5YN/A